Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Koehler, P; Bassetti, M; Chakrabarti, A; Chen, SCA; Colombo, AL; Hoenigl, M; Klimko, N; Lass-Flörl, C; Oladele, RO; Vinh, DC; Zhu, LP; Böll, B; Brüggemann, R; Gangneux, JP; Perfect, JR; Patterson, TF; Persigehl, T; Meis, JF; Ostrosky-Zeichner, L; White, PL; Verweij, PE; Cornely, OA, ;European, Confederation, of, Medical, Mycology;International, Society, for, Human, Animal, Mycology;Asia, Fungal, Working, Group;INFOCUS, LATAM/ISHAM, Working, Group;ISHAM, Pan, Africa, Mycology, Working, Group;European, Society, for, Clinical, Microbiology;Infectious, Diseases, Fungal, Infection, Study, Group;ESCMID, Study, Group, for, Infections, in, Critically, Ill, Patients;Interregional, Association, of, Clinical, Microbiology, and, Antimicrobial, Chemotherapy;Medical, Mycology, Society, of, Nigeria;Medical, Mycology, Society, of, China, Medicine, Education, Association;Infectious, Diseases, Working, Party, of, the, German, Society, for, Haematology, and, Medical, Oncology;Association, of, Medical, Microbiology;Infectious, Disease, Canada.
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
Lancet Infect Dis. 2021; 21(6):e149-e162
Doi: 10.1016/S1473-3099(20)30847-1
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hönigl Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
- Find related publications in this database (using NLM MeSH Indexing)
- Amphotericin B - administration & dosage
- Antifungal Agents - therapeutic use
- Azoles - pharmacology
- COVID-19 - complications
- Coinfection - drug therapy
- Humans - administration & dosage
- Nitriles - administration & dosage
- Pulmonary Aspergillosis - complications, drug therapy
- Pyridines - administration & dosage
- SARS-CoV-2 - administration & dosage
- Triazoles - administration & dosage
- Voriconazole - therapeutic use